SALOUA MABKHOUTI: Open Payments
NPI 1457805475 · WOODBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,630 in 188 payments from 19 companies in 2025. Trend: 2023 $2,830 · 2024 $4,288 · 2025 $3,630
Food & beverage: $3,630
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 48 | $1,399 |
| ABBVIE INC. | 39 | $464 |
| Lilly USA, LLC | 17 | $282 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $265 |
| PFIZER INC. | 15 | $199 |
| Sumitomo Pharma America, Inc. | 13 | $191 |
| Novo Nordisk Inc | 13 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $130 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $75 |
Products named: AIRSUPRA, FARXIGA, VRAYLAR, Kerendia, JARDIANCE, UBRELVY, GEMTESA, TRINTELLIX.
Industry payments across CT — which companies pay providers there.
